Decreased serum osteoprotegerin levels in patients with cardiac syndrome X
Küçük Resim Yok
Tarih
2004
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Receptor activator of nuclear factor kappaB (RANK) and osteoprotegerin (Cl represent the ligand and decoy receptor, respectively, of a pleiotropic cytokine system that regulates bone metabolism and vascular biology. Several studies supported systemic microvascular abnormalities in patients with cardiac syndrome X (CSX). This study investigates serum Cl levels in healthy obese subjects and healthy lean controls affected by cardiac syndrome X. Methods: We compared the Cl levels in 8 patients with cardiac syndrome X [2 males, 6 females; age: 46 +/- 6 yr; body mass index (BMI): 30 +/- 5 kg/m(2)] with 24 obese subjects (8 males, 16 females; age: 38 +/- 5 yr; BMI: 35 +/- 5 kg/m(2)) and 15 healthy lean controls (6 males, 9 females; age: 36 +/- 5 yr; BMI: 23 +/- 2 kg/m(2); BMI<25kg/m(2)). Results: Serum Cl levels in patients with cardiac syndrome X were lower than those in obese subjects and lean controls (11..45 +/- 8.36 pg/ml, 14.78 +/- 8.22 pg/mI, 19.24 +/- 6.96 pg/ml, respectively, cardiac syndrome X vs lean controls, P = 0.039). Conclusions: Serum OPG levels are lower in patients with CSX. Further studies on the mechanisms of OPG in microangiopathy may help to evaluate the OPG system role as a marker for disease activity, prognosis and response to therapy in cardiovascular diseases. (C) 2004, Editrice Kurtis.
Açıklama
13th European Congress on Obesity -- MAY 26-29, 2004 -- Prague, CZECH REPUBLIC
Anahtar Kelimeler
Cardiac Syndrome X, Osteoprotegerin, Microangiopathy, Obesity, Nf-Kappa-B, Coronary Flow Velocity, Microvascular Angina, Rank Ligand, Increase, Receptor, Pain
Kaynak
Journal Of Endocrinological Investigation
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
27
Sayı
9
